CEACAM5

OmniAb Reports First Quarter 2024 Financial Results and Business Highlights

Retrieved on: 
Thursday, May 9, 2024
Health, Stem Cells, Research, Pharmaceutical, Science, Biotechnology, Investment, Teclistamab, Partnership, Myasthenia gravis, Trial of the century, Growth, Hook effect, ASCO, Journal, Lung cancer, Graves' ophthalmopathy, Pharmacokinetics, National Medical Products Administration, Conference, Fluorouracil, Patent, Telephone, NSCLC, Merck Group, Safety, Pembrolizumab, Artificial intelligence, CEACAM5, Autoimmune disease, Immunology, Monoclonal antibody, Clinical trial, University, TED, Sale, Chicken, Bystander effect, Antigen, Neonatal Fc receptor, Patient, Society, Pharmaceutical industry

OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2024, and provided operating and partner program updates.

Key Points: 
  • OmniAb, Inc. (NASDAQ: OABI) today reported financial results for the three months ended March 31, 2024, and provided operating and partner program updates.
  • “The OmniAb team continued to make great progress this past quarter in advancing and expanding our portfolio and partnership base.
  • General and administrative expense was $8.3 million for the first quarter of 2024, compared with $8.2 million for the same period in 2023.
  • As of March 31, 2024, OmniAb had cash, cash equivalents and short-term investments of $69.0 million.

Data Presented at AACR 2024 Showcase Precede Biosciences’ Power to Impact Precision Medicine from a Simple Blood Test

Retrieved on: 
Wednesday, April 10, 2024
MET, Hospital, HER2, HER3, Breast, MD, CEACAM5, Patient, CLDN18, Lung, Health, Biology, AACR, EGFR, Massachusetts General Hospital, Plasma, Pharmaceutical industry

Data further underscore potential to inform therapy selection for antibody drug conjugates and other target-directed therapies across breast, lung, and gastro-esophageal cancers

Key Points: 
  • Data further underscore potential to inform therapy selection for antibody drug conjugates and other target-directed therapies across breast, lung, and gastro-esophageal cancers
    Targets revealed from a single 1mL plasma sample include B7H4, CEACAM5, CLDN18, EGFR, HER2, HER3, MET, NECTIN4, and TROP2
    BOSTON, April 10, 2024 (GLOBE NEWSWIRE) -- Precede Biosciences, a company impacting the development and use of precision medicines with a first-in-class comprehensive epigenomic liquid biopsy platform, today shared three scientific poster presentations from the 2024 American Association for Cancer Research (AACR) Annual Meeting.
  • “The data presented at AACR 2024 add to the growing body of evidence supporting our platform’s unique ability to provide genome-wide insight into the activation status of therapeutic targets, pathways, and resistance mechanisms, all from a simple blood draw,” said Carl Barrett, Chief Scientific Officer of Precede Bio.
  • “As such, we have a significant opportunity to better inform patient selection and enable indication expansion for the many promising agents addressing these targets and pathways with our platform.”
    “Our study highlights the need for new approaches to profile the biology of gastro-esophageal adenocarcinoma, an aggressive disease in which patients can progress quickly,” said Samuel Klempner, MD, medical oncologist at Massachusetts General Hospital and senior author for the abstract on gastro-esophageal cancers.
  • “Precede Bio’s liquid biopsy platform could represent an important advance enabling informed treatment decisions and personalized patient care throughout the cancer journey for this difficult-to-treat cancer.”
    Precede Bio’s posters from AACR 2024 can be found in the presentations section of the company website and are linked directly below:

Press Release: Sanofi announces end of program evaluating tusamitamab ravtansine after a 2L NSCLC Phase 3 trial did not meet a primary endpoint

Retrieved on: 
Thursday, December 21, 2023
Lung cancer, Sanofi, Docetaxel, Glycoprotein, Research, Spacecraft, Apoptosis, Progression-free survival, CEACAM5, Incidence, Cell adhesion, Cancer, Neoplasm, IDMC, Patient, PFS, NSCLC, Vaccine

CARMEN-LC03 trial did not meet dual primary endpoint of improving progression-free survival; tusamitamab ravtansine clinical development program will be discontinued

Key Points: 
  • CARMEN-LC03 trial did not meet dual primary endpoint of improving progression-free survival; tusamitamab ravtansine clinical development program will be discontinued
    PARIS, December 21, 2023.
  • Sanofi is discontinuing the global clinical development program of tusamitamab ravtansine.
  • An Independent Data Monitoring Committee (IDMC) found that tusamitamab ravtansine as a monotherapy did not meet its dual primary endpoint of progression-free survival (PFS) compared to docetaxel.
  • “Our team is grateful to the patients, families and healthcare professionals involved in the tusamitamab ravtansine development program.

Xencor Reports First Quarter 2023 Financial Results

Retrieved on: 
Monday, May 8, 2023
Biotechnology, Health, Pharmaceutical, Clinical Trials, Oncology, ICOS, AACR, CD28, European Alliance of Associations for Rheumatology, Cancer, ENPP3, American Association for Cancer Research, Janssen, TACSTD2, NMOSD, Research, CLDN6, Part, Genentech, Antibody, AstraZeneca, CEACAM5, ASCO, Congress, Patient, STEAP1, Ipilimumab, Colorectal cancer, Vir, EULAR, Cytokine, PD-1, Neuromyelitis optica spectrum disorder, Ovarian cancer, European Alliance, IND, Tumor microenvironment, Roche, Vaccine, Pharmaceutical industry, Cryptocurrency, Video game, EU, MorphoSys, Astellas Pharma, Rheumatology, Alexion, Ravulizumab

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2023 and provided a review of recent business and clinical highlights.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of patients with cancer and autoimmune diseases, today reported financial results for the first quarter ended March 31, 2023 and provided a review of recent business and clinical highlights.
  • In the first quarter of 2023, Xencor earned $10.5 million of royalty revenue from Alexion on net sales of Ultomiris.
  • Revenues for the first quarter ended March 31, 2023 were $19.0 million, compared to $85.5 million for the same period in 2022.
  • ET (1:30 p.m. PT) to discuss the first quarter 2023 financial results and provide a corporate update.

Seagen Reports First Quarter 2023 Financial Results

Retrieved on: 
Thursday, April 27, 2023
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Trastuzumab, Head, NCCN, RAS, Patient, Merck, Spacecraft, BLA, Inc., SGN, Lymphoma, CDE, Accelerated approval (FDA), ADC, Gender representation on corporate boards of directors, Growth, PD-1, Center for Drug Evaluation and Research, FDA, NMPA, Bladder cancer, Hodgkin lymphoma, Abstract, ODE, AACR, American Association for Cancer Research, ADCETRIS, Cohort study, Immunotherapy, National Medical Products Administration, Sanofi, Brentuximab vedotin, Pembrolizumab, Abstract (summary), Clinical trial, Cisplatin, Category, Part, Neck, CEACAM5, ASCO, American Society of Clinical Oncology, Annual general meeting, Society, Pfizer, Pharmaceutical industry, Seagen

Seagen Inc. (Nasdaq:SGEN) (Seagen or the Company) reported financial results today for the first quarter ended March 31, 2023.

Key Points: 
  • Seagen Inc. (Nasdaq:SGEN) (Seagen or the Company) reported financial results today for the first quarter ended March 31, 2023.
  • “Seagen delivered strong performance in the first quarter, with significant growth of 22 percent for both total revenue and net product sales, compared to 2022, driven by our multi-product commercial portfolio,” said David Epstein, Chief Executive Officer of Seagen.
  • Proposed Acquisition of Seagen by Pfizer: In March 2023, Seagen and Pfizer announced they have entered into a definitive merger agreement under which, on the terms and subject to the conditions thereof, Pfizer will acquire Seagen for $229 in cash per Seagen share for a total enterprise value of $43 billion.
  • Revenues: Total revenues for the first quarter of 2023 were $520 million, compared to $426 million for the same period in 2022, primarily driven by growth in net product sales.

Xencor Highlights CD28 Bispecific Antibody Platform at AACR Annual Meeting 2023

Retrieved on: 
Monday, April 17, 2023
Research, Clinical Trials, Stem Cells, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, AACR, Half-life, CD28, CD3, CD86, Cancer, ENPP3, American Association for Cancer Research, TACSTD2, Antibody, CEACAM5, TCR, STEAP1, CD80, Cytokine, Tumor microenvironment, Vaccine

The data were presented in a poster titled “Tumor-specific CD28 costimulatory bispecific antibodies enhance T cell activation in multiple solid tumors” (Abstract 2983) at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida.

Key Points: 
  • The data were presented in a poster titled “Tumor-specific CD28 costimulatory bispecific antibodies enhance T cell activation in multiple solid tumors” (Abstract 2983) at the American Association for Cancer Research (AACR) Annual Meeting in Orlando, Florida.
  • T cells in the tumor microenvironment require engagement of both their T cell receptor (TCR) and their co-stimulatory receptors, like CD28, to achieve full activation.
  • Xencor has developed a modular XmAb® bispecific antibody platform that allows for the rapid generation of drug candidates that co-stimulate CD28 only in the presence of tumor cells and TCR engagement.
  • “We are leveraging the plug-and-play nature of our XmAb bispecific antibody platforms to generate and explore additional CD28 drug candidates against a broader universe of solid tumor targets.”

Xencor to Present Preclinical Data from Novel XmAb® CD28 Bispecific Antibody Programs at the American Association for Cancer Research Annual Meeting 2023

Retrieved on: 
Tuesday, March 14, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Cancer, Tumor microenvironment, AACR, TACSTD2, American Association for Cancer Research, Antibody, Cytokine, Orange County Convention Center, CEACAM5, TCR, STEAP1, CD28, Vaccine

Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will present preclinical data on novel XmAb® CD28 bispecific antibody programs at the American Association for Cancer Research (AACR) Annual Meeting, being held April 14-19, 2023 at the Orange County Convention Center in Orlando, Florida.

Key Points: 
  • Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies and cytokines for the treatment of cancer and autoimmune diseases, today announced it will present preclinical data on novel XmAb® CD28 bispecific antibody programs at the American Association for Cancer Research (AACR) Annual Meeting, being held April 14-19, 2023 at the Orange County Convention Center in Orlando, Florida.
  • “T cells in the tumor microenvironment require engagement of their T cell receptor (TCR) and their co-stimulatory receptors like CD28 to achieve full activation.
  • This is diminished in cancer because tumor cells usually do not express CD28 ligands.
  • We have developed an XmAb antibody platform that allows for the rapid generation of drug candidates that co-stimulate CD28 only in the presence of tumor cells and TCR engagement,” said John Desjarlais, Ph.D., senior vice president and chief scientific officer at Xencor.

Seagen to Present New Clinical and Preclinical Data From Broad Portfolio of Targeted Cancer Therapeutics at the 2023 AACR Annual Meeting

Retrieved on: 
Tuesday, March 14, 2023
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, Cancer, AACR, TIGIT, Spacecraft, Abstract, Tucatinib, HER2, Neck, Partnership, Neoplasm, Head, Research and development, Patient, ADC, Sanofi, CEACAM5, Development, Immunotherapy, Inc., American Association for Cancer Research, Immunoglobulin G, Breast, Pharmaceutical industry, Vaccine, Seagen

Seagen Inc. (Nasdaq: SGEN) today announced the presentation of 17 abstracts featuring new clinical and preclinical data at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place in Orlando from April 14-19, 2023.

Key Points: 
  • Seagen Inc. (Nasdaq: SGEN) today announced the presentation of 17 abstracts featuring new clinical and preclinical data at the upcoming American Association for Cancer Research (AACR) Annual Meeting taking place in Orlando from April 14-19, 2023.
  • The broad range of data being presented at this year’s meeting includes research from Seagen’s approved medicines, as well as data from early-stage clinical, preclinical, and discovery research programs.
  • Other notable clinical data include initial results from a Phase 1 dose-escalation study of SEA-TGT monotherapy in patients with advanced malignancies.
  • Additional preclinical data disclosures are planned, highlighting vedotin programs and novel ADC and tumor targeting technologies, including payloads with immune stimulatory properties.

 EdiGene to Present Latest Research on A Novel Surface Marker and Migration of Hematopoietic Stem Cell (HSC) That Could Enhance HSC Gene Therapy and HSC Transplantation at the 63rd American Society of Hematology (ASH) Annual Meeting and Exposition

Retrieved on: 
Thursday, November 4, 2021
Science, Biotechnology, Research, Pharmaceutical, Oncology, Health, Genetics, Clinical Trials, Stem cell, Society, Cancer, Lists of diseases, CEO, Knowledge, Haematopoietic system, Disease, RNA, Technology, HSC, ASH, CEACAM5, BCL11A, Â, Trial of the century, Research, Health, Polymerization, Transplant, Cell, Patient, Gene editing, CRISPR, Vaccine, Medical device

In a separate presentation, the company demonstrates that short-term microtubule polymerization inhibition could enhance human HSC homing and engraftment.

Key Points: 
  • In a separate presentation, the company demonstrates that short-term microtubule polymerization inhibition could enhance human HSC homing and engraftment.
  • These findings could potentially be used to further optimize HSC gene therapy development and clinical HSC transplantation.
  • EdiGenes ET-01, an investigational gene-editing HSC therapy for patients with transfusion-dependent -thalassemia, is in Phase I clinical study in China.
  • The current research strengthens our efforts to unlock the potential of gene-editing HSC Transplantation, said Dong Wei, Ph.D., CEO of EdiGene.

Global Advanced Non-squamous and squamous NSCLC Pipeline Landscape Report 2021 Featuring F. Hoffmann-La Roche & Sanofi (Tiragolumab & SAR408701) - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 28, 2021
Health, Pharmaceutical, News, Clinical trial, Mergers and acquisitions, II, TIGIT, Therapy, III, Epithelium, CEACAM5, NSCLC, Acquisition, Roche, Sanofi, Discovery, Oil, Generic drug, Pharmaceutical industry

This "Advanced Non-Squamous & Squamous NSCLC - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Advanced Non-Squamous & Squamous NSCLC pipeline landscape.

Key Points: 
  • This "Advanced Non-Squamous & Squamous NSCLC - Pipeline Insight, 2021," report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Advanced Non-Squamous & Squamous NSCLC pipeline landscape.
  • The companies and academics are working to assess challenges and seek opportunities that could influence Advanced Non-Squamous & Squamous NSCLC R&D.
  • The companies which have their Advanced Non-Squamous & Squamous NSCLC drug candidates in the most advanced stage, i.e.
  • Advanced Non-Squamous & Squamous NSCLC: Pipeline Development Activities
    The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage.